MedPath

Bajaj Healthcare Partners with European Firm to Develop Novel API for Clinical Trials

• Bajaj Healthcare has entered into a development and supply agreement with a European entity for a new Active Pharmaceutical Ingredient (API). • The API will initially be supplied in small quantities to the EU partner for clinical trials exploring an alternative indication. • Revenue generation is contingent on positive outcomes from these clinical trials, with potential for larger-scale supply from Bajaj's FDA-approved facility. • This strategic partnership aims to explore new therapeutic applications, leveraging Bajaj Healthcare's manufacturing capabilities.

Bajaj Healthcare has announced a strategic partnership with a European company to develop and supply a novel Active Pharmaceutical Ingredient (API). The collaboration aims to explore new therapeutic applications for the API through clinical trials conducted by the European partner. This move could potentially expand Bajaj Healthcare's market reach and contribute to innovative treatment options.

Development and Supply Agreement

Under the agreement, Bajaj Healthcare will initially supply small quantities of the API to its European partner. These initial supplies will be used to conduct clinical trials to investigate an alternative indication for the drug. The success of these trials is crucial, as further supplies and revenue generation are dependent on positive outcomes.

Manufacturing and Regulatory Compliance

If the clinical trials yield favorable results, Bajaj Healthcare plans to supply the API from its FDA-approved manufacturing facility located in Savli, Vadodara. This facility adheres to stringent quality control measures, ensuring the API meets international regulatory standards. This is a critical factor for the European partner, ensuring the reliability and safety of the API used in their clinical trials.

Financial Performance and Market Position

Bajaj Healthcare, a part of the Bajaj Group, is a prominent API manufacturer based in Thane, with three API plants in Gujarat and Maharashtra. The company's recent financial performance shows signs of recovery, with a net profit of Rs 7.1 crore for the quarter ended June 2024, compared to a loss of Rs 48 crore in the same quarter last year. Revenue from operations also saw a slight increase of 1.9%, reaching Rs 132 crore.

Future Outlook

The partnership with the European entity represents a strategic move for Bajaj Healthcare to diversify its product portfolio and explore new markets. The outcome of the clinical trials will be pivotal in determining the long-term success of this collaboration. Positive results could lead to significant revenue streams and solidify Bajaj Healthcare's position as a key player in the global API market.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Alterity Therapeutics' ATH-434 Shows Promise in Slowing Multiple System Atrophy

Alterity Therapeutics' ATH-434 demonstrated statistically significant slowing of clinical progression in early-stage multiple system atrophy (MSA) patients.
The Phase II trial showed up to 48% of patients experienced a slowing of the disease with the 50mg dose at week 52, as measured by the UMSARS scale.

AVITA Medical's RECELL GO mini Receives FDA Approval for Smaller Wound Treatment

AVITA Medical's RECELL GO mini has been approved by the FDA for treating smaller full-thickness skin defects, up to 480 square centimeters.
The RECELL GO mini utilizes the same processing device as the standard RECELL GO but with a modified cartridge optimized for smaller skin samples, reducing waste.

AstraZeneca's Tezspire Shows Positive Phase III Results for Nasal Polyps

AstraZeneca's Tezspire demonstrated a statistically significant and clinically meaningful reduction in nasal polyp size in a Phase III trial.
The WAYPOINT trial evaluated Tezspire against placebo in adults with severe chronic rhinosinusitis with nasal polyps.

Baili Tianheng's BL-B01D1 Shows Promise in Multiple Phase III Trials

Baili Tianheng reported a significant increase in operating income, driven by an upfront payment from BMS for their BL-B01D1 collaboration.
BL-B01D1 monotherapy is currently undergoing seven Phase III registrational clinical trials across various cancer indications, including lung and breast cancer.

Biofrontera's Ameluz Demonstrates High Efficacy in Phase III sBCC Trial

Biofrontera's Ameluz-PDT therapy met the primary endpoint, showing 65.5% success in complete clearance of superficial basal cell carcinoma (sBCC) lesions, compared to 4.8% with placebo.
The Phase III trial demonstrated that 75.9% of participants treated with Ameluz-PDT achieved complete histological clearance, versus 19% in the placebo group.

Shuttle Pharmaceuticals' Ropidoxuridine Shows Promise in Phase 2 Glioblastoma Trial

Shuttle Pharmaceuticals has successfully dosed the first three patients in a Phase 2 trial of ropidoxuridine for glioblastoma.
The trial is evaluating ropidoxuridine as a radiation sensitizer to enhance the effectiveness of radiation therapy.

Sangamo Therapeutics' Fabry Disease Candidate ST-920 Gains Accelerated Approval Pathway

Sangamo Therapeutics' shares surged after the FDA agreed to a regulatory pathway for accelerated approval of isaralgagene civaparvovec (ST-920) for Fabry disease.
The FDA will consider data from the Phase I/II STAAR trial, using the rate of decline in eGFR at 52 weeks as the primary basis for approval.

Sagimet's Denifanstat Receives FDA Breakthrough Therapy Designation for MASH

Sagimet Biosciences' denifanstat has been granted Breakthrough Therapy Designation by the FDA for treating noncirrhotic MASH with moderate to advanced liver fibrosis.
The designation was based on clinical data demonstrating denifanstat's potential to address the underlying metabolic dysfunction in MASH patients.

OrsoBio Secures $67M for Obesity Drugs, Vor Bio's AML Therapy Shows Promise, and More

OrsoBio, backed by Eli Lilly, raised $67 million to advance its portfolio of weight loss medicines targeting different mechanisms than GLP-1 therapies.
Vor Bio's experimental AML therapy, trem-cel, demonstrated successful engraftment and protection against Mylotarg toxicity in a Phase 1 trial.

AbbVie to Acquire Cerevel, Novartis' Fabhalta Approved, and Other Pharma Updates

AbbVie is set to acquire Cerevel Therapeutics for $8.7 billion, bolstering its neuroscience pipeline with candidates targeting schizophrenia, Parkinson's disease, and mood disorders.
The FDA has approved Novartis' Fabhalta (iptacopan), the first oral monotherapy for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder.

Reference News

[1]
Bajaj Healthcare soars 7% after pact with European firm for new API - Business Standard
business-standard.com · Sep 23, 2024

Bajaj Healthcare's stock surged 6.78% to Rs 404.30 on BSE after announcing a partnership with a European entity for API ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy